Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celltrion Pharm Inc. Issues FY 2012 Outlook


Wednesday, 7 Nov 2012 02:15am EST 

Celltrion Pharm Inc. announced that it expects its fiscal year 2012 revenue, operating profit and net profit to record KRW 52.3 billion, KRW 5.8 billion and KRW 4.5 billion, respectively. 

Latest Developments for Celltrion Pharm Inc

Company Quote

10550.0
-50.0 -0.47%
2:10am EDT